Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Paysign (PAYS) Shares Outstanding (Diluted Average) (2016 - 2025)

Paysign has reported Shares Outstanding (Diluted Average) over the past 15 years, most recently at $59.6 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $59.6 million for Q4 2025, up 7.3% from a year ago — trailing twelve months through Dec 2025 was $59.6 million (up 7.3% YoY), and the annual figure for FY2025 was $59.6 million, up 7.3%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $59.6 million at Paysign, up from $59.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for PAYS hit a ceiling of $59.6 million in Q4 2025 and a floor of $50.4 million in Q1 2021.
  • Median Shares Outstanding (Diluted Average) over the past 5 years was $53.2 million (2022), compared with a mean of $53.9 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): decreased 7.93% in 2021 and later increased 7.3% in 2025.
  • Paysign's Shares Outstanding (Diluted Average) stood at $51.0 million in 2021, then grew by 3.84% to $52.9 million in 2022, then increased by 2.32% to $54.2 million in 2023, then grew by 2.63% to $55.6 million in 2024, then increased by 7.3% to $59.6 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $59.6 million (Q4 2025), $59.0 million (Q3 2025), and $57.9 million (Q2 2025) per Business Quant data.